The Rivkin Center Has Joined OCRA
The Rivkin Center Has Joined OCRA
This historic collaboration unites two respected organizations committed to advancing research for better treatments and a cure for ovarian cancer.
Expanding Research Through Partnership
Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian and gynecologic cancer nonprofit, is proud to announce that the Rivkin Center for Ovarian Cancer Research has combined with OCRA.
Please explore the resources below to learn more about the support and tools available from OCRA.
Support & Resources
Research
Center for Public Policy
Get Involved
OCRA Rivkin Family SummeRun
Join thousands of participants of all ages and fitness levels at Seattle’s Seward Park to raise awareness and fund critical research for ovarian cancer. Registration opens in early April.
About
Related Topics
September is Gynecologic and Ovarian Cancer Awareness Month
About Gynecologic and Ovarian Cancer Awareness Month September is recognized nationwide as Gynecologic and Ovarian Cancer Awareness Month, a dedicated time to raise awareness for all gynecologic cancers. Throughout the month, OCRA joins forces with patients, caregivers, and supporters to amplify our voices. We focus on educating the public about risks and symptoms, highlighting the … Continued
The Overview: July 2026
SummeRun Raises $260,000+ for Research, Hope and Progress Nearly one thousand runners, walkers, survivors, families, friends, and supporters showed up at Seattle’s Seward Park on Sunday, July 12th, for the 33rd annual Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than $260,000 for research and programs that support the gynecologic cancer community. The … Continued
Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources
In an article published by Everyday Health, “Coping With the Emotional Challenges of Platinum-Resistant Ovarian Cancer” (June 10, 2026), Ovarian Cancer Research Alliance (OCRA) community member Amanda Widro shares her experience navigating a platinum-resistant ovarian cancer diagnosis. Ovarian cancer is considered platinum-resistant when it recurs within six months of finishing platinum-based chemotherapy. Widro, who was … Continued